Language    ES     EN

the company

Microviable Therapeutics is located in Asturias (northern Spain), and our main objective is to develop products based in intestinal microbiota, mainly with therapeutic or co-adjuvant purposes, to restore the intestinal dysbiosis associated with several diseases. Examples of these are antibiotic-associated diarrhoea or inflammatory bowel diseases.



Microviable Therapeutics is in process of developing a kit designed for the collection, storage and transport of fecal samples. This will allow processing intestinal microbiota in a way that long-term viability will be ensured. Currently, we also have a catalog of different services related to microbiota analisis. Further information is provided using the contact form at the bottom of this site.



We are developing different products, based on viable and well-characterised gut microbiota, focused on the restauration of the intestinal ecosystem after disrupting treatments, such as prolonged antibiotic intake or pelvic radiotherapy. We are also developing biotherapeutics for the treatment in which an altered microbiota is detected.



Microviable Therapeutics SL is integrated by a multidisciplinary team of researchers with expertise in intestinal microbiota and human health, as well as experts in marketing, business and administration. In addition, we have a network of collaborators in different hospitals, universities and research centers, both at national and international levels.



Publication of a method for intestinal microbiota isolation using density gradients (Hevia et al., 2015).


Patent registered. Title: Device for collecting and transport of samples in anaerobiosis. Registration number P201630176. Deposited on 16/02/2016 in the Spanish Patent and Trademark Office (SPTO). PCT application PCT/ES2017/070087 (15/02/2017).


Prize "Radar Spin-Off", granted by CEEI Asturias ( Microviable Therapeutics starts its activity. The society is founded as a spin-off of the Dairy Research Institute (IPLA), which belongs to the National Research Council of Spain (CSIC).


XI Prize to the best Biotechnology Enterprize granted by CEEI. Signature of the agreement allowing Microviable to hire part of the installations of the Dairy Research Institute (IPLA-CSIC).


Microviable is funded in a specific call of the IDEPA ( for developing methodologies focused on maintaining the long-term viability of the gut microbiota.

intestinal dysbiosis

Intestinal dysbiosis can be defined as any alteration in the relative composition of the microbial populations of our gut, in comparison to a healthy status or eubiosis. Perhaps one of the most evident dysbiosis examples is the antibiotic-associated diarrea, in which the intestinal microbiota is mostly removed favoring pathogen proliferation such as Clostridium difficile.

Other diseases or intestinal conditions in which an intestinal dysbiosis has been described, which relative higher prevalence rates in Spain, such as Intestinal Bowel Disease (11,820 cases), Irritable Bowel Syndrome (3,700,000 cases), Colo-rectal cancer (32,240 cases), Obesity (10,000,000 cases), Metabolic Syndrome (10,800,000 cases), Type-1 Diabetes (9,454 cases) or Rheumatoid Arthritis (470,000 cases) (Extracted from the annual report of the Spanish Ministry of Health, Social Services and Equallity, 2012). In Microviable Therapeutics we are very interested in the Antibiotic-Associated Diarrhea, with an incidence of 136,138 cases/year in Spain, From them, 7,601 cases develops Clostridium difficile-associated diarrhea.

Infections caused by Clostridium difficile consists of recurrent diarrhea episodes, often bloody and painful. Mortality rate is estimated in 30%. To date, there is no treatment assuring complete healing, so the patient is often suffering from 2-3 relapses per year. Burden for the Spanish National Health System are about 32,157,093 €/year (Revista Española Salud Pública, (2013) 87: 25-33). In these cases, many gastroenterology societies recomends fecal microbiota transplant (FMT) as therapy of choice, due mainly to the current remission rates of around 90%. On the contrary, remission rates for inflammatory bowel diseases after FMT are lower (60% for Crohn's Disease (n=38; 24% for Ulcerative Colitis (n=123) (Curr. Opin. Gastroenterol. 2016, 32:282-286)


If you are interested in analyse your intestinal microbiota with the latest technologies based on massive sequencing of microbial DNA, we are your laboratory.

IMPORTANT INFORMATION: our services can only be granted under medical prescription. If you are a physician/enterprise interested in hiring our services, please use the contact form at the bottom of the website.

Service 1: Analysis of the composition of the intestinal microbiota from microbial DNA. The objective of this service is to deeply characterise the relative abundances of the different microbial populations, as well as their metabolic potential. In addition we can offer comparison of this data against whole microbiome datasets, determination of changes in microbial populations in defined poblational groups, after different treatments such as drugs, probiotics etc.

Service 2: Detection of a wide array of biochemical, molecular, immunological or microbiologial markers of diverse gut alterations such as inflammation.

We offer our services to any customer interested in the exact composition of his/her intestinal microbiota. We also offer these services to health professionals, public or private, interested in the relationships of microbial populations or certain markers with the symptoms of their patients. Finally, we will also consider to directly serve public and private hospitals, notably those interested in include these kind of analysis in their service offer. Our prices can be consulted using the contact form.

R+D+I project

Microviable Therapeutics develops its main research and development lines in restoring the microbial ecosystem in all those physiological conditions or diseases where the appearence of dysbiosis can be predicted. In these cases, the intestinal microbiota can be previously extracted, stored and conserved preserving its viability to perform an auto-transplant after the treatment. If this is not possible, our microbiota-based products will allow FMT allways following clinical recommendation.

The intestinal microbiota of the patient can be isolated and stored before being subjected to a treatment disturbing or eliminating the normal populations of gut microbes. In this way the initial microbial ecosystem can be restored through auto-transplant after the treatment is finished. This project, which includes development and marketing of a commercial kit for sample collection and transport ensuring bacterial viability, is in progress.

In Microviable Therapeutics we are focusing some of our research efforts in the formulation of normalized microbiotas with therapeutical applications for Clostridium difficile-associated diarrhoea (CDAD) and inflammatory bowel diseases (IBD).


Microviable Therapeutics has been founded by five scientific promoters. Four of them belongs to IPLA-CSIC. All of them have extensive experience in the field of intestinal microbiota and related domains.


Noelia Martínez, PhD

Responsible of R+D+I. Noelia obtained her PhD in the University of Oviedo. She has been postdoctoral researcher of the IPLA-CSIC between 2008-2016. She has experience in fast microorganism detection by culture-independent techniques, molecular biology, genetic engeering, proteomics and transcriptomics.

Abelardo Margolles, PhD

Senior researcher at the IPLA-CSIC; permanent staff. He obtained his PhD in the University of Santiago de Compostela. His main research lines are focused in understanding the relationship of the human intestinal microbiota with health and diet.


Susana Delgado, PhD

Postdoctoral researcher at the IPLA-CSIC, she obtained her PhD by the University of Oviedo. Her PhD work consisted on the analysis of healthy intestinal microbiotas. From them, she has worked in different institutions in research lines related to the factors conditioned the appearance of intestinal dysbiosis in humans.

Borja Sánchez, PhD

Borja defended his PhD in the University of Oviedo; he is senior researcher and permanent staff at the IPLA-CSIC. His main research line is devoted to the understand the molecular mechanisms of host-bacteria interaction through extracellular and surface-associated proteins/peptides, with the application of omics and bioinformatics. More info .


Claudio Hidalgo, PhD

Postdoctoral researcher of the IPLA-CSIC and located at the University Hospital of Asturias. He has experience in probiotic characterization and in metabolism/physiology of representatives of the human gut microbiota. He is currently studying the response of the immune system to certain surface-associated proteins from probiotic bacteria.

MT team is completed with the participation of "AsturHealth Soluciones Innovadoras en Salud, S.L." experts in bussiness and marketing of health-related products. Its staff has MBAs in commercial direction and marketing, human resources, financial direction, management and stratetic direction in the main Spanish Business Schools. They account for more than 20 years of experience working for some of the many biomedical multinationals, holding responsability positions in the areas of marketing/bussiness development, regulatory environments, distribution and corporate finances.

contact form

Microviable Therapeutics offers, mainly to health professionals and enterprises but also to anybody interested, many services related to gut (or other body locations) microbiota analysis.

contact information

  • Email:


Email sent!
We will answer your query asap.